| INTRODUCTION
Stroke is a leading cause of disability and death, especially in developed countries. Ischemic stroke accounts for approximately 85% of all cases of stroke (Koton et al., 2014) . Despite significant progress in our understanding of the pathophysiology of stroke, few effective treatments are available at present. Here, we focus on survivin, a member of the inhibitors of apoptosis protein (IAP) gene family, which acts upstream of the caspase death cascade to prevent caspase activation, thereby halting apoptotic cell death (Baratchi, Kanwar, & Kanwar, 2010) . Previously, we reported that survivin is a downstream gene target of STAT3 and plays a critical role in the neuroprotective effect of estradiol on the CA1 region of the hippocampus after global ischemia (Sehara et al., 2013) . Here, we report the neuroprotective effect of survivin using the more clinically relevant model of transient middle cerebral artery occlusion (MCAO) in rats.
Many rodent models of stroke in which stroke is induced by intraluminal transient or permanent MCAO, surgical MCAO, photothrombosis, or endothelin-1 have been used in studies of focal cerebral ischemia (Fluri, Schuhmann, & Kleinschnitz, 2015) . Among these models, transient MCAO by intraluminal suture can reproduce the conditions of ischemia-reperfusion after endovascular thrombectomy (EVT) for ischemic stroke.
In the suture MCAO model, a suture is introduced directly into the internal carotid artery, advanced until it interrupts the blood supply to the MCA, and removed 60-90 min after transient occlusion (Engel, Kolodziej, Dirnagl, & Prinz, 2011) . Recent randomized controlled trials including the MR CLEAN (Berkhemer et al., 2015) , ESCAPE , EXTEND-IA (Campbell et al., 2015) , and SWIFT PRIME (Saver et al., 2015) trials have been carried out to determine the benefits of recanalization of intracranial large artery occlusion with endovascular intervention in the acute phase of ischemic stroke in humans. With recent advances in EVT therapy, the significance of the suture MCAO model which was also used in this study has become increasingly evident.
To examine the role of survivin in the ischemic boundary zone after transient MCAO, we overexpressed survivin by intraparenchymal injection of adeno-associated virus (AAV) vector. Among the many virus vector systems, AAV and lentivirus systems are now widely used to deliver genes to the central nervous system due to their safety and efficacy. Indeed, AAV vectors has been used in many phase I and phase II clinical trials without complications (Hwu et al., 2012; Leone et al., 2012; Mittermeyer et al., 2012; Muramatsu et al., 2010; Rafii et al., 2014) . AAV is a nonenveloped, single-stranded DNA virus of the Parvoviridae family with a small particle size of 20-25 nm (Atchison, Casto, & Hammon, 1965; Rose, Berns, Hoggan, & Koczot, 1969) . AAV is an icosahedral virus particle that consists of 60 copies of the three viral capsid proteins: VP1, VP2, and VP3 (Chamberlain, Riyad, & Weber, 2016) . Certain exposed capsid regions are thought to define tissue tropism, and more than one hundred variants of AAVs have been isolated from humans and nonhuman primates to date (Gao et al., 2004) . Among these, the most extensively studied AAV serotypes in the central nervous system (CNS) are 1, 2, 5, 8, 9, and rh10 (Hocquemiller, Giersch, Audrain, Parker, & Cartier, 2016) . AAV9 and rh10 have been reported to show widespread CNS transduction and to have a natural ability to pass through the blood-brain barrier (BBB) (Swain et al., 2014; Tanguy et al., 2015) . Although these serotypes circumvent the BBB, intraparenchymal injection is still the most common route of administration to the CNS in animal studies and clinical trials because of its region selectivity for gene delivery, less need for a high virus titer and no need for evaluation of preexisting immunity (Saraiva, Nobre, & Pereira de Almeida, 2016) . However, intravenous systemic injection has recently been used in clinical trials due to its low level of invasiveness. The administration route should be determined depending on the purpose and conditions of the trial.
The purpose of this study is to test the possibility of neuroprotection of AAV-mediated survivin overexpression in the ischemic boundary zone using a rat suture MCAO model.
| MATERIALS AND METHODS

| Plasmid construction and recombinant
AAV production
The coding sequence of rat survivin was PCR-amplified using specific primers(forward: 5′-ATGGGTGCTCCGGCGCTG CCCC-3′; reverse: 5′-TCAGCGTAAGGCAGCCAGCTGC TCA-3′) and the 429-bp fragment was cloned into the multiple cloning site of the pMD20-T vector (Takara Bio, Japan) followed by digestion of the resulting plasmid with BamHI and XbaI and ligation of the resulting fragment into BamHI/XbaIdigested pFastBacHT A (Thermo Fisher Scientific, MA) to add a 6 × His tag sequence at the 5′ end of the survivin construct. Subsequent cloning into the p1.1c vector was performed using an In-Fusion HD cloning kit (Takara Bio, Japan) (vector forward: 5′-ACCCTCACTAAAGGGAACAAA-3′; vector reverse: 5′-CCGGTGTCTTCTATGGAGGT-3′; fragment forward: 5′-CATAGAAGACACCGGATGTCGTACT ACCATCACC-3′; fragment reverse: 5′-CCCTTTAGTGA GGGTCAAGCTTGGTACCGCATG-3′), and followed by cloning into a pAAV-human recombinant green fluorescent protein (hrGFP) vector (Agilent Technologies, CA) to obtain pAAV-cytomegalovirus promoter (CMV)-6 × His-survivin. Correct cloning was confirmed by sequence analysis (Eurofins, Luxembourg). Recombinant AAV-CMV-hrGFP and AAV-CMV-survivin (serotype rh10) were prepared as previously described (Kurosaki et al., 2017 confluent human embryonic kidney cells (HEK293; Agilent Technologies) were incubated in large culture vessels and cotransfected with an AAV vector plasmid, adenoviral helper plasmid pHelper (Agilent Technologies), and pAAV2 Rep/ AAVrh10. Crude viral lysates were purified using an AAV purification kit (Takara Bio, Japan). Viral titers were determined by quantitative PCR of the CMV sequence, and the viral stock in this study was diluted with phosphate buffer saline (PBS) and adjusted to the final concentration of 2 × 10 9 viral genomes (vg)/μl.
| Animals
All of the experimental procedures were approved by the Animal Research Ethics Board of Jichi Medical University. Male Sprague-Dawley rats (4 weeks old, body weight 100-120 g) were purchased from Japan Charles River (Japan). The animals were group housed in the animal holding facility of the Jichi Medical University under ad libitum access to food and water.
| Stereotaxic injection
The rats were anesthetized with 2% isoflurane and placed in a stereotaxic apparatus (Narishige, Japan). Viral stocks of AAV-CMV-hrGFP (n = 9) or AAV-CMV-His-survivin (n = 5) or PBS (n = 8) were injected through a 36-gauge glass cannula connected to a 10-μl Hamilton syringe mounted on a microinjection pump (Univentor, Malta) at a rate of 0.2 μl/ min. The stereotaxic injection coordinates for the striatum were 0.5 mm anterior to the bregma, 2.5 mm right of the midline, and 4.5 mm below the pial surface with 2 μl injection (4 × 10 9 vg in total). The needle was kept in place for another 5 min before the cannula was slowly withdrawn, in order to prevent reflux. The skin incision was closed with a suture and the animal was kept warm with a heat blanket before being returned to the cage. Rats were housed under diurnal lighting conditions with free access to food and water.
| Transient middle cerebral artery occlusion
Three weeks after stereotaxic injection, infarcts were induced by transient MCAO as described previously (Sehara et al., 2007) . Rats were anesthetized with 2% isoflurane. A middle neck incision was made and the right common carotid artery was exposed. A 4-0 surgical nylon monofilament blunted at the tip was introduced into the right internal carotid artery through the external carotid stump and advanced 18 mm past the carotid bifurcation. The filament was left in place for 90 min and then withdrawn. Body temperature was maintained at 37 ± 0.5°C with heating pads until the animals had recovered from surgery. In the total of 14 rats (including sham-operated animals)
in which MCAO was induced in this study, two rats died after surgery. Sham-operated rats were treated identically except that the MCAs were not occluded after the neck incision (n = 4).
| Neurologic characterization
Before Nissl staining, a neurologic test was carried out 24 hr after MCAO (Longa, Weinstein, Carlson, & Cummins, 1989) . From the results of the tests, animals were scored as: 0 = no deficit; 1 = failure to extend the contralateral forepaw fully; 2 = circling to the ipsilateral side; 3 = falling to the contralateral side; and 4 = no spontaneous walking with a depressed level of consciousness.
| Cerebral infarct measurement
After neurologic evaluation at 24 hr after transient MCAO, the rats were decapitated under deep anesthesia with an overdose of pentobarbital via the intraperitoneal route. The brains were quickly removed, frozen in powdered dry ice, and stored at −80°C. For frozen sectioning, coronal brain sections of 10 μm in thickness were prepared on a sliding microtome (Leica, Germany). Brain sections were collected serially at 0.4-mm intervals from 2.0 mm anterior to 0.8 mm caudal to the bregma (total of eight slices/ animal), stained with 0.1% cresylviolet, and scanned with a scanner (GT-X970; Epson, Japan). The border between infarcted and noninfarcted tissues was traced. To compensate for the effect of brain edema, corrected infarct area was calculated using the following formula: corrected infarct area = contralateral hemisphere area − (ipsilateral hemisphere − infarction area) (Swanson et al., 1990) . Infarction area was expressed as a percentage of the contralateral hemisphere.
| Immunohistochemistry
The sections made previously were incubated with a primary antibody against the 6×-His tag (diluted at 1:1000, ab5000, Abcam, UK), active caspase-3 (diluted at 1:1000, ab2302, Abcam, UK), or myeloperoxidase (MPO; diluted at 1:1000, ab9535, Abcam, UK) in PBS containing 0.3% Triton X-100 at 4°C overnight followed by incubation with a secondary antibody against anti-mouse IgG (diluted at 1:1000, #4409, Cell Signaling, MA, USA) or anti-rabbit IgG (diluted at 1:1000, A-11010, Thermofisher Scientific, MA, USA) for 1 hr at room temperature. After washing with PBS, the sections were coverslipped with a mounting agent including 4′6-diamino-2-phenylindole (DAPI; Thermofisher Scientific, MA, USA). Immunoreactivity was visualized using a microscope (BZ-9000; Keyence, Japan). For quantitative analysis, cells positive for active caspase-3-and MPO at 200× magnification were counted using a BZ-II analyzer (Keyence, Japan). The proportion of doublepositive cells in DAPI-positive cells was calculated in four separate visual fields of ischemic boundary zones per rat.
| Terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling (TUNEL) staining
To detect DNA strand breaks in apoptosis, the sections were reacted with a TUNEL mixture for 1 hr in the dark after fixation and permeabilization according to the manufacturer's instructions (Roche, Germany). For quantitative analysis, TUNEL-positive cells at 200× magnification were counted using the BZ-II analyzer. The proportion of double-positive cells in DAPI-positive cells was calculated in four separate visual fields of ischemic boundary zones per rat.
| Statistical analysis
The results are presented as means ± SEM. Statistical analysis were performed using GraphPad Prism 6.0. Statistical comparisons between two groups was conducted using Student's t test. Statistical comparisons between three groups were conducted using one-way ANOVA with Tukey's posthoc test. Statistical comparisons of neurological evaluation by Longa score were conducted using Kruskal-Wallis test with Dunn's posthoc test. Statistical significance was defined as p < 0.05.
| RESULTS
| AAV-rh10 delivered the transgene widely in the injected side of the striatum
To evaluate the distribution of AAV-rh10 expression in the control animals, we measured the GFP-positive area 3 weeks after stereotaxic injection of the virus vector aiming at the right striatum. In the animals treated with a vehicle (PBS), we found no GFP signal in the striatum. In the AAV-treated animals, we found broad expression of GFP in the right striatum (calculated volume: control: 0 vs. AAV-rh10: 14.5 ± 0.9 mm 3 , p < 0.0001, compared with the control) (Figure 1 ).
| Survivin overexpression via the AAV vector reduced cerebral infarction area after MCAO
To evaluate the neuroprotective effect of survivin, we injected AAV-GFP or AAV-His-survivin into the right striatum 3 weeks before MCAO induction. Twenty-four hours after MCAO, the rats were killed for histological analysis after neurological scoring. ANOVA revealed significant differences in neurological scores (p = 0.0061, Kruskal-Wallis statistic 8.556) and the posthoc test indicated that the neurological scores of the AAV-GFP group showed a significant functional deficit compared to the sham-operated group (sham vs. AAV-GFP, p = 0.0198; sham vs. AAV-His-survivin, p = 0.0647; AAV-GFP vs. AAV-His-survivin, p > 0.9999) (sham: 0, AAV-GFP: 3.5 ± 0.3 vs. AAV-His-survivin: 3.3 ± 0.3) (Figure 2a ). Nissl staining was performed to determine the infarction area, and corrected infarction area was calculated to avoid the effect of postischemic edema. The sham control animals showed no infarction (n = 4). ANOVA revealed significant differences in infarction area 3 weeks after PBS or AAV injection (F 2,9 = 261.3, p < 0.0001) and the posthoc test indicated that AAV-His-survivin injection resulted in a significant reduction of infarction area compared to that after AAV-GFP injection (AAV-GFP: 67 ± 3% vs. AAV-Hissurvivin: 51 ± 2%, p = 0.0017) (Figure 2b and c) . In the sham control animals, no GFP signal or His-tag immunoreactivity was found. In the Figure 1 shows transgene expression in the striatum of the control animals 3 weeks after vector injection, which would cover most of the region of the ischemic boundary zone after MCAO. After MCAO, GFP signals disappeared in the damaged region of AAV-GFP-injected animals ( Figure 3a ). In the ischemic boundary zone, we found GFP signals in the AAV-GFP-injected rats and His-tag immunoreactivity in the AAV-His-survivin rats (Figure 3b and c).
| Survivin overexpression did not change neutrophil infiltration after MCAO
To determine the effect of survivin on neutrophil infiltration, we counted the number of cells that were immunoreactive to MPO. In the sham control animals, no cells positive for MPO were found. Twenty-four hours after MCAO, we found cells positive for MPO in the ischemic core and ischemic boundary zone in both the AAV-GFP and AAV-His-survivin groups. In the ischemic boundary zone, ANOVA revealed significant differences in proportion of cells positive for MPO (F 2,9 = 21.63, p = 0.0004) and the posthoc test demonstrated no significant difference between the proportions of cells positive for MPO in the AAV-GFP and AAV-Hissurvivin groups (AAV-GFP: 35 ± 4% vs. AAV-His-survivin: 30 ± 6% per visual field, p = 0.7017) (Figure 4 ).
| Survivin overexpression reduced apoptosis in the ischemic boundary zone after MCAO
To determine the effects of survivin on apoptosis, we counted the numbers of cells positive for active caspase-3 and TUNEL.
In the sham control animals, small number of cells positive for caspase-3 and no TUNEL-positive cells were found. Twentyfour hours after MCAO, we found cells positive for active caspase-3 and TUNEL in the ischemic core and ischemic boundary zone in both the AAV-GFP and AAV-His-survivin groups. In the ischemic boundary zone, ANOVA revealed significant differences in proportions of active caspase-3-and TUNEL-positive cells (F 2,9 = 43.63, p < 0.0001; F 2,9 = 190.1, p < 0.0001, each), and the posthoc test demonstrated that the AAV-His-survivin group showed fewer cells positive for active caspase-3 and TUNEL than those in the AAV-GFP group (sham 6.8 ± 2.6%, AAV-GFP: 32.0 ± 1.8% vs. AAV-Hissurvivin: 22.2 ± 1.0% per visual field, p = 0.0147; sham: 0%, AAV-GFP: 66.0 ± 2.4% vs. AAV-His-survivin: 49.5 ± 3.5% per visual field, p = 0.0029, each) (Figures 5 and 6 ).
| DISCUSSION
In the present study, we showed a neuroprotective effect of an antiapoptotic factor, survivin, by using AAVrh10-mediated overexpression in a transient focal ischemia model of rats. Because of their long-term expression and safety, AAVs have been used in many clinical trials of CNS disorders including Parkinson disease (Eberling et al., 2008; Muramatsu et al., 2010 ), Alzheimer's disease (Rafii et al., 2014) , spinal muscular atrophy (oral communication ASGCT 2017, abstract 291), and others ( Figure 6 ). Many previous studies using animal models of ischemic stroke have shown the effectiveness of AAV-mediated transfer of genes including bcl-2 (Shimazaki, Urabe, Monahan, Ozawa, & Kawai, 2000) , glial cell line-derived neurotrophic factor, cytochrome c-initiated activation of apoptotic protease activating factor-1 (Apaf-1) (Cao et al., 2004) , vascular endothelial growth factor (VEGF) (Shen et al., 2006) , netrin-1 (He et al., 2013; Lu et al., 2012) , glutamate transporter (GLT-1) (Harvey et al., 2011) , adiponectin (Miao et al., 2013) , and brain-derived neurotrophic factor (BDNF) (Yu et al., 2013) . However, AAVs were administered 5 days to 3 weeks prior to the induction of ischemia in those studies because virus vectors take some time to express transgenes. Although we also performed intraparenchymal injection of AAV-His-survivin 3 weeks before MCAO and successfully showed a neuroprotective effect of survivin in this focal ischemia model, in future clinical applications, gene therapy for ischemic stroke would require selection of patients who are expected to suffer from ischemic stroke in the near future such as patients who have crescendo recurrent transient ischemic attacks and patients who are going to receive highrisk elective endovascular surgery. A few recent studies have shown that postischemic gene transfer via an AAV vector had some desirable effects. Zhu et al. (2009) showed that AAVmediated insulin-like growth factor 1 (IGF-1) transduction 24 hr after MCAO promoted angiogenesis and neurogenesis in the ischemic boundary zone (no mention of functional outcome). Sun et al. (2011) showed that AAV-mediated netrin-1 transduction 1 hr after MCAO promoted angiogenesis and neurogenesis in the ischemic boundary zone but did not reduce stroke volume. Furthermore, Li et al. (2014) showed that AAV-mediated stromal cell-derived factor-1α transduction 1 week after MCAO not only promoted neurogenesis and angiogenesis but also improved behavioral outcomes and reduced postischemic brain atrophy, which is the only study showing that intraparenchymal injection of a virus vector after MCAO improved histological and functional outcomes. Postischemic administration of a virus vector would be more clinically relevant than preischemic administration as long as it is effective.
The advantage of intraparenchymal injection is that we can express genes of interest where we aim to express them. In this study, we preliminarily determined the appropriate injection site for the ischemic boundary zone after MCAO, and our data showed that 4 × 10 9 vg of a virus vector was distributed widely around the injection site (Figure 1) . Recently, AAV capsids have been artificially modified to increase transduction efficiency and circumvent the BBB. A viral capsid, PHP. eB, has recently been reported to have high transduction efficiency for the CNS after systemic administration. PHP.eB was identified from a genetically manipulated AAV capsid library (Chan et al., 2017) . Intravenous administration of AAV vectors may become more widely used also in the stroke research field. Our results did not show a significant improvement of functional outcome in the AAV-His-survivin group compared to that in the AAV-GFP group (Figure 2 ). Either 60-or 90-min MCAO was used for rats in many previous studies. Thus, one possibility is that our 90-min MCAO might have been fierce and that the lesion that is protectable by survivin overexpression might not be so large. Since a neuroprotective effect was evident in histological analysis, shorter MCAO might show a difference in functional outcome.
It is well established that an inflammatory response that follows acute ischemic stroke is detrimental to the brain. Brain ischemia releases several damage-associated molecules that trigger a sterile inflammatory response. The first immune cells to respond are the brain-intrinsic microglia, followed by neutrophils, which exacerbate oxidative stress and BBB damage (Chamorro, Dirnagl, Urra, & Planas, 2016). Thus, neutrophils can be therapeutic targets in ischemic stroke. Our results showed that the percentage of cells positive for MPO in the ischemic boundary zone was not significantly different in the AAV-GFP and AAV-His-survivin groups, indicating that the neuroprotective effect of survivin overexpression may not be due to an anti-inflammatory mechanism. However, it should be noted that many of the markers associated with neutrophils can also be present on other immune cells, which means that we do not have markers specific to neutrophils. MPO, which is often used as a marker of neutrophils, is also expressed by monocytes and microglia (Jickling et al., 2015) .
Survivin is a member of IAP family that directly binds and inhibits the activity of caspase-9 and executor caspases-3 and -7, leading to a halt of the apoptotic process (Villapol, Acarin, Faiz, Castellano, & Gonzalez, 2008) . In transient global ischemia that causes selective, delayed death of hippocampal CA1 pyramidal neurons, Li et al. and our group reported that survivin plays a critical role in estradiol neuroprotection (Li, Xia, & Chen, 2011; Sehara et al., 2013) . Li et al. intraperitoneally administered an estradiol derivative, 2-methoxyestradiol (2ME2), after global ischemia and showed that 2ME2 increased surviving neurons and reduced TUNEL-positive cells in CA1 region after global ischemia. Our study also showed that active caspase-3-and TUNELpositive cells were significantly reduced in the ischemic boundary zone after MCAO. Although neuronal death in the ischemic core after MCAO is caused by mechanisms different from those of global ischemia (Krafft et al., 2012) , neuroprotection by survivin overexpression may be due to the same mechanism, an antiapoptotic effect.
Since AAV vector expression persists for a long time as we previously reported for a monkey that showed expression 15 years after intraparenchymal injection , the capacity of gene therapy for ischemic stroke remains, especially in high-risk cases.
